INTRODUCTION {#s1}
============

Type B acute aortic dissection (AAD) is a life-threatening emergency, which is associated with high morbidity and mortality rates \[[@R1]\]. Despite clinical advancements to aid in early diagnosis, as well as surgical and endovascular therapies, the mortality rate for type B AAD in the acute phase remains high. Data from the International Registry of Acute Aortic Dissection (IRAD) indicate that in-hospital mortality rate of patients with type B AAD was 9.2%, and it was similar among patients undergoing endovascular repair and those who are medically managed \[[@R2]\]. Therefore, predictive tools that can identify patients with type B AAD at increased risk of death in the acute phase are critical for risk stratification and treatment decisions. Some clinical prognostic markers for AAD have been identified, including old age \[[@R2]\], female sex \[[@R3]\], hypotension \[[@R2]\], impaired renal function \[[@R4]\], and hypoalbuminemia \[[@R5]\]. Some others markers, such as maximum aortic diameter and false lumen closure status, are evaluated using computed tomography (CT) \[[@R6], [@R7]\]. However, the anatomy of aortic dissection is often complex and might not be consistent, especially during the early hospital stay. It is therefore challenging to evaluate the severity of AAD from these parameters alone, in the early phase of admission.

Tolenaar and colleagues attempted to design a simple prediction model using variables that are independently associated with in-hospital mortality in patients with type B AAD, including age, hypotension/shock, periaortic hematoma, descending aorta diameter, mesenteric ischemia, acute renal failure, and limb ischemia \[[@R2]\]. However, it is challenging for physicians to identify high-risk patients with type B AAD in the early phase, especially in the emergency room. Inflammatory response and thrombosis play an important role in the progression of AAD; thrombo-inflammatory status is associated with the severity and type of AAD, and correlates with adverse outcomes \[[@R8], [@R9]\]. Our previous study indicated that a novel prognostic score based on thrombo-inflammatory status (Simplified Thrombo-Inflammatory Prognostic Score, sTIPS) was a useful tool for stratifying high-risk patients with type A AAD, irrespective of surgical or medical treatment \[[@R10]\]. However, it was unclear whether sTIPS could also predict mortality in patients with type B AAD; we thus conducted the present study to investigate the association between sTIPS and the risk of in-hospital mortality in patients with type B AAD.

MATERIALS AND METHODS {#s2}
=====================

This was a single-center, retrospective cohort study, to evaluate the association between sTIPS and in-hospital

mortality risk, in patients with type B AAD. The study complied with the Declaration of Helsinki, and the study protocol was approved by the Human Ethical Committee of West China Hospital of Sichuan University.

Patient selection and endpoints {#s2_1}
-------------------------------

We retrospectively reviewed hospital records between November 2012 and September 2015, at West China Hospital of Sichuan University. Records of all hospitalized patients diagnosed with type B AAD were screened. The inclusion criteria were as follows: type B AAD presenting within 14 days of onset of symptoms, and dissection of descending aorta with presence of both, true and false lumen confirmed on CT with contrast. The exclusion criteria were, patients with malignant tumor (three patients), infectious diseases (nine patients), history of chronic liver disease (five patients), and splenomegaly (two patients). Additionally, 18 patients were excluded because the auxiliary examination could not be conducted. Finally, 491 patients with type B AAD were enrolled in this study. The primary endpoint was all-cause mortality.

Data collection {#s2_2}
---------------

Clinical data of each patient was extracted from clinical notes and charts in the hospital. These included demographic data, cardiovascular risk factors, past medical history, results of blood tests at admission, electrocardiographic and CT findings, details of therapies, drug treatments during the hospital stay and at discharge, and occurrence of in-hospital death. The Modification of Diet in Renal Disease equation was used to estimate glomerular filtration rate in milliliters per minute per 1.73 m^2^ \[[@R11]\].

Simplified thrombo-inflammatory prognostic score {#s2_3}
------------------------------------------------

sTIPS is described in our previous study \[[@R10]\]; in the present study, it was calculated from data obtained on the day of admission. Patients with both, white blood cell count (WBC) \> 10 (10^9^/L) and a mean platelet volume to platelet count (MPV/PC) ratio \> 7.5 (10^2^fL/10^9^L^-1^) were assigned a score of 2, while patients showing elevations in either only one or none of the parameters, were assigned scores of 1 and 0, respectively.

Statistical analysis {#s2_4}
--------------------

Data were calculated as frequencies and percentages for categorical variables, and as mean ±SD for continuous variables (normal distribution) or median and interquartile ranges (abnormal distribution). Patient characteristics were compared based on sTIPS values. Parametric patient characteristics were compared using a one-way ANOVA, whereas nonparametric characteristics were compared using the Kruskal-Wallis H test. Categorical data were compared using the chi-square (χ^2^) test. Kaplan-Meier curves were constructed and stratified according to sTIPS. Cox proportional hazards models were used to investigate the relationship between sTIPS and time-to-mortality during hospitalization. To construct the Cox model, univariate Cox regression for each predicting variable was performed, with all-cause mortality as the outcome variable. Variables that were found to be significant (*P* \< 0.05) on univariate Cox models were then entered into a multivariable Cox model. From the multivariable model, we identified variables that were significant (*P* \< 0.05) predictors of mortality. Data analysis was performed using SPSS Statistics for Windows, Version 21.0 (Chicago, IL, USA: SPSS Inc.).

RESULTS {#s3}
=======

Baseline patient characteristics {#s3_1}
--------------------------------

In this study, 491 patients with type B AAD were enrolled to investigate the association between sTIPS and the risk of in-hospital death. Of 491 patients, 24 patients (4.9%) died during hospitalization. Of these, 16 patients died of rupture of the aortic dissection, 4 of myocardial infarction, and 2 each of shock and acute kidney failure. The mean age of patients was 53 ± 13 years; 425 patients (86.6%) were male, 135 patients (27.5%) received medication, 337 patients (68.6%) received endovascular therapy, and 19 patients (3.9%) underwent surgery. Of these, 17 (12.6%), 6 (1.8%), and 1 (5.3%) on medication, endovascular therapy, and surgery, respectively, died during hospitalization. The median time of presentation from onset of symptoms was 0.98 (0.5-1.9) days. The median duration of hospital stay was 14 (3-20) days.

Baseline characteristics of the study cohort classified by sTIPS, are shown in Table [1](#T1){ref-type="table"}. Age, WBC, MPV/PC ratio, albumin level, uric acid level, and prevalence of hypertension and smoking were significantly different among the three sTIPS groups. Other clinical characteristics did not vary significantly by sTIPS (Table [1](#T1){ref-type="table"}).

###### Relationships between clinical characteristics and the sTIPS in patients with type B acute aortic dissection.

  Variables                          sTIPS0 (*n*=194)   sTIPS1 (*n*=228)   sTIPS2 (*n*=69)   *P*- value
  ---------------------------------- ------------------ ------------------ ----------------- ------------
  Age (years)                        54±13              51±12              53±13             0.021
  Males, *n* (%)                     160 (82.5)         203 (89.0)         62 (89.9)         0.099
  Hypertension, n (%)                161 (83.0)         166 (72.8)         57 (82.6)         0.026
  Coronary artery disease, *n* (%)   5 (2.6)            7 (3.1)            3 (4.3)           0.746
  Marfan syndrome, *n* (%)           1 (5.2)            2 (8.8)            1 (1.4)           0.752
  Diabetes mellitus, *n* (%)         27 (13.9)          21 (9.2)           10 (14.5)         0.249
  Smoking, *n* (%)                   86 (44.3)          122 (53.5)         42 (60.9)         0.035
  Admission SBP (mmHg)               145±26             151±28             158±27            0.001
  Admission DBP (mmHg)               87±17              90±20              93±19             0.065
  Admission heart rate (beats/min)   82±14              86±15              86±17             0.009
  **Blood parameters**                                                                       
  WBC (109/L)                        7.3±1.8            12.1±4.2           13.0±3.1          \<0.001
  Platelet count(109/L)              212(168-274)       177(135-227)       125(112-136)      \<0.001
  MPV (fL)                           10(9.1-10.9)       10.9(9.8-12.0)     12.2(10.9-13.2)   \<0.001
  MPV/PC ratio (102fL/109L-1)        4.1±2.1            6.3±3.6            10.5±3.3          \<0.001
  Hemoglobin (g/L)                   122±22             129±23             130±23            0.004
  Creatinine (umol/L)                78(60-93)          84(71-102)         82(65-103)        0.015
  eGFR (mL/min)                      100(65-132)        119(88-161)        117(78-154)       0.001
  Urea nitrogen (mmol/L)             6.3±3.7            7.5±6.9            6.9±3.8           0.102
  Albumin (g/L)                      34±6               36±6               36±5              0.010
  Uric acid (mmol/L)                 289(211-346)       311(242-415)       294(231-348)      0.003
  TC (mmol/L)                        2.60±1.78          2.67±1.58          2.82±1.56         0.667
  TG (mmol/L)                        2.67±1.48          4.97±1.58          2.36±1.46         0.339
  HDL-C (mmol/L)                     0.87(0.64-1.11)    1.01(0.72-1.30)    1.06(0.85-1.46)   0.002
  LDL-C (mmol/L)                     2.27±0.70          2.20±0.72          2.19±0.69         0.595
  Direct bilirubin (umol/L)          3.18(2.15-5.20)    3.90(2.08-5.80)    5.70(3.00-7.79)   \<0.001
  Indirect bilirubin (umol/L)        11.2±7.2           13.5±9.1           15.4±8.2          \<0.001
  Total bilirubin (umol/L)           15.7±8.9           19.4±11.4          21.6±9.6          \<0.001
  AST (IU/L)                         19(16-29)          23(18-34)          25(19-37)         0.007
  Lactate dehydrogenase (IU/L)       158(139-185)       178(154-220)       185(161-259)      \<0.001
  Creatine kinase (IU/L)             53(34-76)          82(43-184)         80(43-219)        \<0.001
  CK-MB (IU/L)                       5.55(1.74-8.50)    6.30(1.58-11.15)   4.90(1.58-10.0)   0.080
  LVEF (%)                           62±7               62±9               63±7              0.596
  **Types of treatment, *n* (%)**                                                            **0.957**
  Endovascular therapy               135 (69.6)         153 (67.1)         49 (71.0)         
  Surgery                            7 (3.6)            9 (4.0)            3 (4.4)           
  Medication                         52 (26.8)          66 (28.9)          17 (24.6)         
  **Medication in hospital**                                                                 
  ARB/ACEI, *n* (%)                  94 (48.5)          98 (43.0)          37 (53.6)         0.242
  CCB, *n* (%)                       165 (85.1)         185 (81.1)         52 (75.2)         0.185
  Beta-blockers, *n* (%)             173 (89.2)         214 (93.9)         64 (92.8)         0.206
  Diuretics, *n* (%)                 49 (25.3)          73 (32.0)          25 (35.6)         0.140
  Sodium nitroprusside, *n* (%)      113 (58.2)         119 (52.2)         43 (62.2)         0.239

MPV, mean platelet volume; eGFR, estimated glomerular fltration rate; TC, total cholesterol; TG, total glyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; AST, aspertate aminotransferase; CK-MB, creatine kinase isoenzyme; sTIPS, the Simplified Thrombo-Inflammatory Prognostic Score; SBP, systolic blood pressure at admission; DBP, diastolic blood pressure at admission; LVEF, left ventricular ejection fraction; WBC, white blood cell; MPV/PC ratio, mean platelet volume to platelet count ratio; ARB, angiotensin II receptor; ACEI, angiotensin-converting enzyme inhibitor; CCB, calcium-channel blocker

STIPS and in-hospital mortality {#s3_2}
-------------------------------

The in-hospital mortality rate of patients gradually increased as sTIPS increased; the mortality rate of patients with a score of 2 was 2.7 and 6.2 times higher than that in patients with scores of 1 or 0, respectively (Figure [1A](#F1){ref-type="fig"}). Kaplan-Meier survival analysis showed that the cumulative mortality rate was significantly greater in patients with higher sTIPS (*P* = 0.001; Figure [1B](#F1){ref-type="fig"}). Subgroup analysis by treatment type indicated that the cumulative survival rate was lower in patients with higher sTIPS in the medication only group (*P* = 0.012; Figure [2A](#F2){ref-type="fig"}), as well as the endovascular therapy group (*P* = 0.001; Figure [2B](#F2){ref-type="fig"}). We did not analyze the relationship between score and in-hospital mortality of patients undergoing surgery as only one patient in this group died in the hospital.

![A. the short-term mortality in different thrombo-inflammatory prognostic score (sTIPS) patients with type B acute aortic dissection; B. Kaplan-Meier analysis survival curve according to different sTIPS in patients with type B acute aortic dissection (0 score:![](oncotarget-08-79315-g003.jpg), 1 score:![](oncotarget-08-79315-g004.jpg), 2 score:![](oncotarget-08-79315-g005.jpg))](oncotarget-08-79315-g001){#F1}

![A. Kaplan-Meier analysis survival curve according to different thrombo-inflammatory prognostic score (sTIPS) in patients with type B acute aortic dissection receiving medication therapy\
**B.** Kaplan-Meier analysis survival curve according to different sTIPS in patients with type B acute aortic dissection receiving endovascular therapy. (0 score:![](oncotarget-08-79315-g003.jpg), 1 score:![](oncotarget-08-79315-g004.jpg), 2 score:![](oncotarget-08-79315-g005.jpg)).](oncotarget-08-79315-g002){#F2}

Univariate Cox survival regression showed that sTIPS was positively related with the risk of all-cause mortality. Other variables that were significant in univariate Cox models are shown in Table [2](#T2){ref-type="table"}. After adjusting for these potential confounders, the multivariable Cox survival regression indicated that high sTIPS continued to show a positive association with the risk of mortality. For sTIPS of 0, 1, and 2, the adjusted hazard ratios (HRs) \[95% confidence intervals (95% CI)\] for in-hospital mortality were 1.0 (ref.), 1.918 (95% CI: 1.134-3.537) (*P* = 0.045), and 4.704 (95% CI: 1.184-18.685) (*P* = 0.028), respectively (Table [2](#T2){ref-type="table"}).

###### Cox regression of short-term all-cause mortality for patients with type B acute aortic dissection.

  Variables               Univariate analysis   Multivariate analysis                                     
  ----------------------- --------------------- ----------------------- ---------- ------- -------------- -------
  STIPS                                                                 0.002                             0.016
  STIPS1 (*vs*. STIPS0)   2.389                 1.761-7.501             0.036      1.918   1.134-3.537    0.043
  STIPS2 (*vs*. STIPS0)   6.717                 2.068-21.813            0.002      4.704   1.184-18.685   0.028
  WBC \>10 (109/L)        3.414                 1.355-8.600             0.009      3.373   0.378-30.076   0.276
  Heart rate              1.046                 1.023-1.069             \< 0.001   1.009   0.971-1.048    0.649
  Hypoalbuminemia         3.776                 1.393-10.235            0.009      5.639   1.503-21.156   0.010
  LDL-C                   0.345                 0.164-0.724             0.005      0.437   0.190-1.006    0.437
  Total bilirubin         1.033                 1.002-1.065             0.034      1.029   0.990-1.069    0.143
  Indirect bilirubin      1.040                 1.003-1.079             0.033      1.053   1.004-1.104    0.034
  AST(per 10 IU/L)        1.011                 1.005-1.018             0.001      1.027   0.997-1.058    0.776
  LDH (per 10 IU/L)       1.010                 1.005-1.014             \<0.001    1.005   0.995-1.016    0.340
  CK (per 100 IU/L)       1.013                 1.005-1.022             0.001      1.014   0.981-1.048    0.404
  CK-MB (per 10 IU/L)     1.076                 1.027-1.127             0.002      0.913   0.732-1.138    0.417
  Urea nitrogen           1.084                 1.059-1.110             \< 0.001   1.067   1.017-1.118    0.007
  Cr (per 10 umol/L)      1.030                 1.017-1.044             \< 0.001   1.033   1.005-1.062    0.021
  eGFR (per 10 mL/min)    1.014                 1.008-1.020             \< 0.001   1.015   1.002-1.028    0.024
  Uric acid               1.006                 1.003-1.009             \< 0.001   1.005   1.000-1.010    0.043
  Types of treatment                                                    \< 0.001                          0.037
  Medication              1                                                        1                      
  Endovascular therapy    0.133                 0.052-0.337             \< 0.001   0.227   0.071-0.728    0.013
  Surgery                 0.393                 0.052-2.955             0.364      0.246   0.015-4.154    0.331

sTIPS, the Simplified Thrombo-Inflammatory Prognostic Score; HR, hazard ratio; CI, confidence interval

DISCUSSION {#s4}
==========

The present study indicated that a higher sTIPS correlated with a more complex baseline clinical patient risk profile, and that in-hospital mortality occurred more frequently in the group with higher sTIPS. When including sTIPS in a multivariable Cox regression model after adjusting for confounding factors, an elevated sTIPS was the most significant determinant of in-hospital mortality. Thus, our results suggest that the sTIPS may be able to stratify type B AAD patients based on mortality risk, in the early phase of admission.

AAD is characterized by intimal tear and surging of blood into the media layer of the artery, leading to the formation of a false lumen and subsequent systemic inflammatory responses \[[@R12]\]. Inflammation plays an important role in the development of AAD, and inflammatory cells such as lymphocytes and macrophages have been detected in medial degeneration \[[@R12], [@R13]\]. Furthermore, AAD patients with higher inflammatory cell activity in the aortic wall seemed to have a high risk for disease progression and poorer prognosis in the acute phase \[[@R14]\]. Moreover, several inflammatory markers such as interleukin-6 (IL-6), C-reactive protein (CRP), matrix metalloproteinases-9 (MMP-9), and WBC at admission were reportedly associated with the severity of systemic inflammatory response and adverse outcomes in patients with type A AAD \[[@R13], [@R15]-[@R19]\]. Similarly, high WBC at admission, platelet to lymphocyte ratio, and neutrophil to lymphocyte ratio were correlated with increased in-hospital mortality risk for type B AAD \[[@R20]-[@R22]\]. In contrast to studies reporting positive associations between CRP level at admission and risk of death in type A AAD, some studies have failed to find associations between baseline CRP and mortality risk in type B AAD patients \[[@R23], [@R24]\]. With respect to WBC, the predictive value for mortality in patients with AAD was not consistent \[[@R23], [@R25]\]. Regarding some other biomarkers such as cardiac troponin level at admission, there are conflicting reports about their accuracy to predict in-hospital mortality for patients with type A AAD \[[@R19], [@R26]\]. It appears that predicting adverse outcome in patients with type B AAD, based on biomarkers at admission, is more difficult compared to predicting for type A AAD. The association of these inflammatory biomarkers might be significantly affected by a time-dose expression curve or time-dependent changes, and thus their clinical value might be greatly compromised. A single biomarker might therefore only occasionally predict the prognosis of type B AAD.

Thrombosis is associated with the pathogenesis of AAD \[[@R27], [@R28]\]. Platelets play an important role in thrombosis, and are the first cellular components that adhere to the damaged vessel walls, followed by leukocytes, after an aortic intimal tear. This forms a thrombosis in the false lumen and modulates inflammatory activity \[[@R7], [@R13], [@R27]\]. Platelet activity is a predictor for thrombotic burden \[[@R29]\], and platelet indices at admission including PC, MPV, and MPV/PC ratio are useful markers for estimating platelet activity; MPV/PC ratio has been reported to be a better marker than MPV or PC alone \[[@R30], [@R31]\]. A previous study determined that PC was independently associated with in-hospital mortality in type A AAD, and among those undergoing surgical intervention \[[@R32]\].

Thrombocytopenia at admission was also a predictor of late mortality (50.8 months) in type B AAD by Cox proportional-hazards analysis in a small cohort study of 77 patients \[[@R33]\]. Our previous study indicated that an elevated MPV/PC ratio at admission was a strong independent predictor for in-hospital complications and long-term mortality (3.5 years) in patients with type A AAD \[[@R34]\]. Further, type A AAD patients with D-dimer at admission above 20 mg/mL had higher in-hospital mortality, but the predictive value became invalid after surgical intervention \[[@R25]\]. However, some studies did not find any association between PC or D-dimer values at admission and mortality in type B AAD patients \[[@R20], [@R35]\]. Given the inconsistent results, it remains unclear whether PC, D-dimer, or other markers of thrombosis at admission are predictive of in-hospital complications and long-term mortality among type B AAD patients.

Thrombo-inflammatory status can reflect the nature and severity of cardiovascular disease, and could be associated with other pathophysiological processes \[[@R9]\]. However, neither inflammatory nor thrombotic markers alone, might be particularly predictive of AAD; thus, a multi-biomarker strategy that combines biomarkers across patho-biological axes of inflammation and thrombosis provides incremental prognostic information for prediction of AAD \[[@R8], [@R10], [@R36]\]. To verify the hypothesis, we combined WBC (an inflammatory biomarker) and MPV/PC ratio (a thrombotic biomarker) at admission, into a novel and simplified thrombo-inflammatory prognostic score, and found that this score was independently predictive of in-hospital complications and long-term mortality in patients with type A AAD with higher sensitivity and specificity compared to WBC or MPV/PC ratio alone \[[@R10]\]. In the present study, we found that WBC or MPV/PC ratio alone were not independent predictors for in-hospital mortality in patients with type B AAD. However, when sTIPS was included in the multivariable Cox model, it could stratify high-risk patients with type B AAD in the hospital independently. Therefore, sTIPS might be a simple and effective prognostic evaluation tool combining both inflammatory and thrombotic biomarkers, and might be more practical for clinicians to identify high-risk patients with type B AAD, offering higher sensitivity and specificity, especially in the emergency room.

Recent studies revealed that false lumen circumferential extent, maximum aortic diameter, and false lumen thrombosis, were also helpful in identifying high-risk patients with type B AAD \[[@R37]\]. However, the anatomy of aortic dissection often changes during the course of type B AAD, and even after surgery and endovascular therapy. Our previous study showed that residual patent false lumen is independently associated with poor long-term survival in AAD. However, only type B AAD patients with partial false lumen thrombosis had an increased late mortality risk; this association was not found in type A AAD after surgery \[[@R7]\]. The sTIPS score predicted mortality and reflected systemic thrombo-inflammatory status irrespective of various therapies, and was more stable than CT markers. Therefore, a more accurate prognosis might be achieved by adding sTIPS to the current model.

LIMITATIONS {#s5}
===========

Our analysis has several limitations. First, this study was a retrospective single-center cohort study, and many confounding factors might have affected the outcomes. In addition, we did not follow up with the patients, and could not investigate the association between sTIPS and long-term outcomes in type B AAD. Second, we recorded the WBC and MPV/PC ratio at admission, but the changes in these markers at different time points were not recorded; a series of measurements at different time points during hospitalization might be more valuable for evaluation of the association between sTIPS and prognosis of type B AAD. Third, we did not measure other inflammatory and thrombotic biomarkers, such as IL-6, MMP-9, CRP, and D-dimer, and investigate the relationship between these biomarkers and adverse outcomes in type B AAD. Fourth, we did not have data on the CT anatomical parameters of the included patients; hence, we could not compare the predictive value of anatomical parameters for in-hospital mortality of patients with type B AAD. Therefore, prospective, large-scale multicenter studies are required to confirm our results.

CONCLUSIONS {#s6}
===========

In conclusion, the sTIPS is a useful score reflecting the overall inflammatory-thrombotic status, and was a powerful predictor of in-hospital mortality among patients with type B AAD, irrespective of the type of therapy. The sTIPS may be therefore able to risk-stratify type B AAD patients at admission for in-hospital outcomes such as mortality in the early phase.
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